Hoey Investments Inc. raised its position in iShares Biotechnology ETF (NASDAQ:IBB – Free Report) by 83.3% in the first quarter, according to its most recent disclosure with the SEC. The firm owned 8,263 shares of the financial services provider’s stock after acquiring an additional 3,755 shares during the period. iShares Biotechnology ETF makes up about 0.2% of Hoey Investments Inc.’s holdings, making the stock its 26th largest position. Hoey Investments Inc.’s holdings in iShares Biotechnology ETF were worth $1,395,000 at the end of the most recent reporting period.
Other large investors also recently modified their holdings of the company. Citigroup Inc. grew its position in iShares Biotechnology ETF by 40.9% in the 4th quarter. Citigroup Inc. now owns 5,242,688 shares of the financial services provider’s stock valued at $884,808,000 after purchasing an additional 1,521,992 shares during the period. Morgan Stanley lifted its stake in shares of iShares Biotechnology ETF by 2.5% in the fourth quarter. Morgan Stanley now owns 3,204,126 shares of the financial services provider’s stock valued at $540,760,000 after buying an additional 76,978 shares in the last quarter. BNP Paribas Financial Markets lifted its stake in shares of iShares Biotechnology ETF by 11.4% in the fourth quarter. BNP Paribas Financial Markets now owns 2,133,461 shares of the financial services provider’s stock valued at $360,064,000 after buying an additional 218,066 shares in the last quarter. Raymond James Financial Inc. grew its holdings in shares of iShares Biotechnology ETF by 286.2% during the fourth quarter. Raymond James Financial Inc. now owns 994,311 shares of the financial services provider’s stock valued at $167,810,000 after buying an additional 736,881 shares during the last quarter. Finally, LPL Financial LLC grew its holdings in shares of iShares Biotechnology ETF by 145.9% during the fourth quarter. LPL Financial LLC now owns 992,799 shares of the financial services provider’s stock valued at $167,555,000 after buying an additional 589,033 shares during the last quarter. 62.45% of the stock is currently owned by institutional investors.
iShares Biotechnology ETF Price Performance
NASDAQ:IBB opened at $196.83 on Tuesday. iShares Biotechnology ETF has a one year low of $128.06 and a one year high of $198.13. The firm has a 50-day moving average of $173.66 and a 200-day moving average of $172.05.
iShares Biotechnology ETF Cuts Dividend
iShares Biotechnology ETF Company Profile
iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.
Featured Articles
- Five stocks we like better than iShares Biotechnology ETF
- Big Beautiful Boycott: Can It Really Hurt Coca-Cola, Amazon, and Kraft Heinz Stocks?
- 3 Stocks With Solid Yields and Sustainabale Payouts Boost Dividends Once Again
- 2 Short Squeezes for Summer Speculation: What the Bears Are Getting Wrong
- How TeraWulf’s Anthropic Deal Booted Up a $19B AI Empire
Receive News & Ratings for iShares Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.
